Instill Science

A place to discuss science, share work, and find mentors and collaborators

Instill Science / post-0pM6yzru
September 21, 2023jessica-sacher
IND Biotech news Lysins

Contrafect, a company developing ‘direct lytic agents’ (which include lysins and amurin peptides), has submitted an IND application for preliminary approval of a new IV antibacterial agent for treatment of hospital-acquired and ventilator-associated bacterial pneumonia.

Loading ...
No comments yet. Be the first to comment!